NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Zhang D, Harris HM, Chen J, Judy J, et al. Blood 2023;141:1584-1596.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhang D, Harris HM, Chen J, Judy J, et al. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood 2023;141:1584-1596.
PMID: 36375120